Success story medac
The Hamburg pharmaceutical company medac Gesellschaft für klinische Spezialpräparate mbH conducts research, develops and distributes therapeutic agents and diagnostic products in the areas of oncology, urology and autoimmune diseases. Besides the production of established medicinal products, the company focuses on new research and further development of tailor-made therapeutic agents in order to provide individual therapies for patients. Founded in 1970, medac today employs a staff of more than 1,000 and is represented worldwide via subsidiaries and distribution partners.
The challenge: Transparency in line with IT access rights
Who has which IT access rights within the company and why, who grants these rights, and when were such rights granted – all this information pertaining to legal structures is reviewed by authorities in line with audits in pharmaceutical companies as well. Furthermore, there are clear international guidelines (e. g. GAMP) calling for a high level of transparency when it comes to the granting of access rights. Before the implementation of daccord, medac had to invest a lot of time and effort into making the granting of IT access rights transparent. This was a time-consuming process and also cost a lot of money – and the responsibility was exclusively with the IT department. In addition, the option to document the latest status of access rights in reports was missing. All this was to be changed.